Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan

Abstract

Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without RBV are efficacious and generally well tolerated for treatment of HCV-1b patients in Taiwan.

Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non‐cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis

“…The rate of pruritus in our patients was 19.6%, which was higher than the reported rates in patients without severe renal impairment receiving PrOD (5.3-8.7%). 33,34 However, the rate was consistent with the findings in RUBI-1 and RUBY-II studies in patients with severe renal impairment receiving PrOD (15-18%). 35 We speculated that the ritonavir-induced inhibition of bile salt export pump may be exaggerated in hemodialysis patients, resulting in more pronounced spillover of bile acids into the systemic circulation that potentiated pruritus.…”

“…14,[16][17][18][19] In addition, the on-treatment HCV virokinetics in our hemodialysis patients were comparable with the ordinary patients, implying that the potency of PrOD is similar between patients with or without renal impairment. 33 However, the on-treatment HCV virokinetics did not have a role in predicting SVR 12 rate because there were no differences in SVR 12 rates in our patients with varied viral decline rates.…”

Sofosbuvir‐based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection

“…Compared with most protease inhibitor-containing DAA regimens that are not active against HCV-2 infection, SOF in combination with RBV or various kinds of NS5A inhibitors have been Sofosbuvir for hepatitis C genotype 2 recommended by the guidelines for HCV-2 patients with excellent safety and efficacy. 32,33 Furthermore, these regimens have fewer potential drug-drug interactions than protease inhibitor-containing regimens. 34 Based on these advantages, treatment by SOF in combination with RBV or NS5A inhibitors is appealing to clinicians in the management of HCV-2 infection.…”

Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection

“…Although SOF plus RBV, LDV or DCV, elbasvir (EBR) plus grazoprevir (GZR), and paritaprevir/ritonavir plus ombitasvir and dasabuvir (PrOD) are approved to treat HCV in patients with and without HIV coinfection, these regimens are limited in clinical practice by efficacy, pill burden, DDI and genotype/subtype coverage . VEL/SOF‐based IFN‐free DAAs have relatively lower pill burden, broad genotype/subtype spectrum, few DDI, excellent efficacy and safety, and can be applied to patients with decompensated cirrhosis .…”